文献速递乳房整形与再造

进退两难:脱细胞真皮基质与美国食品药品监督管理局上市前批准——我们如何构建研究?

Catch-22: Acellular Dermal Matrix and U.S. Food and Drug Administration Premarket Approval-How Can We Construct Studies?
PubMed 文献 · Plast Reconstr Surg · 2022-09-27

本文为专题文章,回顾脱细胞真皮基质(ADM)在乳腺手术中的使用历史,并描述美国食品药品监督管理局(FDA)与ADM之间关系的持续演变。FDA在调查乳房植入物相关间变性大细胞淋巴瘤时声明ADM未获批用于乳房再造,在乳腺手术中使用被视为超说明书使用。

要点

  • ADM作为人组织来源生物制品,最初作为软组织支撑产品无需上市前批准。
  • ADM在乳腺手术中快速普及并用于多种应用。
  • FDA声明ADM未获批用于乳房再造,乳腺手术中使用属超说明书使用。

核心结论

  • 本文详述ADM在乳腺手术中的历史及FDA与ADM关系的持续演变。

研究设计与样本

  • 专题文章,回顾ADM在乳腺手术中的使用历史及FDA与ADM关系演变。

主要发现

  • ADM作为人组织来源生物制品,最初作为软组织支撑产品无需上市前批准。
  • ADM自首次用于乳腺手术以来促进了乳房再造的诸多进展,并快速普及、频繁用于多种应用。
  • FDA在调查乳房植入物相关间变性大细胞淋巴瘤潜在因素时声明ADM未获批用于乳房再造,乳腺手术中使用被视为超说明书使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a biologic product derived from human tissue, acellular dermal matrices did not require premarket approval for their initial use as a soft-tissue support product. Since their first use in breast surgery, acellular dermal matrices have allowed for numerous advances in breast reconstruction. They quickly gained popularity in breast surgery and are used frequently in various applications. During an investigation into potential factors leading to breast implant-associated anaplastic large-cell lymphoma, the U.S. Food and Drug Administration made an official statement that acellular dermal matrices were not approved for use in breast reconstruction and that using them in breast surgery was considered off-label. This special topic article details the history of acellular dermal matrices in breast surgery and describes the ongoing evolution of the relationship between the U.S. Food and Drug Administration and acellular dermal matrices.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Boyd CJ, Bekisz JM, Choi M, et al. Catch-22: Acellular Dermal Matrix and U.S. Food and Drug Administration Premarket Approval-How Can We Construct Studies? Plast Reconstr Surg. 2022. PMID: 36161788. doi:10.1097/PRS.0000000000009701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。